Posted on

WEGE Secures Project to Construct Coordinating Ministry for Maritime and Investment Affairs Office Complex at IKN

JAKARTA, Feb 2, 2023 - (ACN Newswire via SEAPRWire.com) - PT Wijaya Karya Bangunan Gedung Tbk (WEGE) has secured another project at the new capital city (Ibu Kota Negara, IKN) in East Kalimantan to construct the office complex for the Coordinating Ministry for Maritime and Investment Affairs (Kementerian Koordinator Kemaritiman dan Investasi, Kemenkomarves). The project was valued at Rp745 billion. WEGE has previously secured a project to construct modular buildings to house construction workers at IKN, and its progress has reached 94%.A highlight of the eight storey Kemenkomarves office is it features integrated Smart and Green Building concept.Another highlight is that the construction of the Kemenkomarves Office will implement Building Information Modelling (BIM) technology. The Kemenkomarves Office is located at Sepaku, Penajam Paser Utara and will not be far from the IKN Presidential Office.WEGE's scope of work in this project is design-build construction with a completion period of 660 working days. The Kemenkomarves office complex will cover an area of 24,274 square metres.WEGE Carries Out Groundbreaking of BMKG State College that Applies Smart and Green Building ConceptWEGE held a groundbreaking ceremony of the Lecture and Laboratory Building (Centre of Excellence) for the departments of Meteorology, Climatology, Geophysics, and Instrumentation (MKGI) of the State College of Meteorology Climatology and Geophysics (STMKG) in Tangerang.The groundbreaking ceremony was held on Monday (24/01) and attended by the Head of Meteorological, Climatological, and Geophysical Agency (BMKG), Dwikorita Karnawati; Head of STMKG, I Nyoman Sukanta; representative of the Tangerang City Government; President Director of WEGE, Hadian Pramudita; Director of QHSE and Marketing, Yulianto; and Director of Operations I, Bagus Tri Setyana."We hope that through Smart and Green Building concept, BMKG is contributing to reducing and controlling CO2 emissions," said the Head of BMKG, Dwikorita Karnawati in her speech.WEGE was trusted by BMKG to construct the MKGI Lecture and Laboratory Building (Centre of Excellence) located at Jalan Meteorologi No. 5, Tanah Tinggi, Tangerang, Banten.This modern campus with the Smart and Green Building concept is scheduled for completion in 350 calendar days or at the end of 2023. Construction of this BMKG state college implemented level 5D of BIM technology to support the acceleration, construction accuracy, and safety and security factors.WEGE's scope of work in this project includes planning, preparation, structural work, architectural work, mechanical, electrical & plumbing (MEP) work, and landscaping.This STMKG facility will be 39 metres high, consisting of eight floors and one basement level with a total building area of 31,540 square metres.In addition to constructing a lecture building, there will be an MKGI Laboratory (Centre of Excellence) which targets the Excellent category in Green Building Certification.This is one of BMKG's mega projects in training experts to support BMKG's duty in providing information on meteorology, climatology, geophysics, and air quality to the Indonesian people.PT Wijaya Karya Bangunan Gedung Tbk [IDX: WEGE]Contact: Purba Yudha TamaCorporate Secretary PT Wijaya Karya Bangunan Gedung Tbk. Mobile: 0813 1792 5577Phone: +6221 85908862 / 85909003Email: corsec@wikagedung.co.id Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

LUI Che Woo Prize donates RMB 250 million to support the development of Shanghai Jiao Tong University Zhangjiang Science Park, The new campus is named Lui Che Woo Science Park

HONG KONG, Dec 20, 2022 - (ACN Newswire via SEAPRWire.com) - Dr Lui Che-woo, Chairman of K. Wah Group (the "Group") and the founder of LUI Che Woo Prize - Prize for World Civilization ("LUI Che Woo Prize"), has donated RMB 250 million through the LUI Che Woo Prize to support the development of Shanghai Jiao Tong University ("SJTU") Zhangjiang Science Park and contribute to national science and technology development. To thank Dr Lui for his generous donation, the new campus will be named Lui Che Woo Science Park. The agreement signing ceremony was held in Hong Kong today, guests including HKSAR Chief Executive John Lee who gave a video speech; former Chief Executive Carrie Lam, Executive Director of K. Wah International Holdings Limited ("KWIH") Alexander Lui, Executive Director of KWIH and member of board of trustees of SJTU Paddy Lui, Secretary of the CPC SJTU Committee Yang Zhen Bin; and Vice President of SJTU Zhang An Sheng. Professor Lin Zhong Qin, President of SJTU, and other university leaders participated in the ceremony via webcast. After the ceremony, Professor Ding Kui Ling, Executive Vice President of SJTU, Academician of the Chinese Academy of Sciences and Dean of the Zhangjiang Institute for Advanced Study, delivered a keynote speech on China's Forefront Science and Technology Development through a live webcast to promote the exchange of science and technology development and ties between Shanghai and Hong Kong.A rendering of Lui Che Woo Science Park in completion.1. Lui Che Woo Science Park Block 1: AI Biomedicine Centre, DNA Storage and Research Centre; 2. Block 2: Integrated Scientific Innovation Research Centre; 3. Block 3: AI Cybersecurity Innovation Centre; 4. Block 4: Frontiers Science Centre for Transformative Molecules, Future Material Creation Centre; 5. Block 5: Ultra-Fast Science Centre; 6. Science Park Complex; 7. Teacher and student dormitory; 8. Teacher and student dormitory; 9. The adjacent Shanghai Synchrotron Radiation FacilityDr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization (middle) and Yang Zhen Bin (2nd left), Secretary of the CPC SJTU Committee sign the donation agreement, accompanied by Alexander Lui (2nd right), Executive Director of K. Wah International Holdings Limited; Paddy Lui (1st right), Executive Director of K. Wah International Holdings Limited and member of board of trustees of SJTU; and Zhang An Sheng (1st left), Vice President of SJTU.Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization (1st row – 2nd right), Yang Zhen Bin (1st row - 2nd left), Secretary of the CPC Shanghai Jiao Tong University ("SJTU") Committee, former chief executive Carrie Lam (1st row – 1st right), Zhang An Sheng (1st row – 1st left), Vice President of SJTU, take a group photo with the representatives from the LUI Che Woo Prize, members of board of trustees, and representatives from the SJTU.Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization delivers a speech.John Lee, HKSAR Chief Executive, gives a video speechThe agreement signing ceremony was webcast live at the lecture hall of the "Lui Che Woo Science Park" of Shanghai Jiao Tong University.Nurture new generations of scientists with SJTU to benefit mankind through scientific research and development ("R&D")SJTU is a well-known comprehensive university located in Shanghai. It plays a crucial role in the national innovation strategy and supports technological development, with a profound impact on the future of China and the wellbeing of people. In 2014, President Xi Jinping expressed hope of developing Shanghai into a technological innovation hub. The National Development and Reform Commission and the Ministry of Science and Technology then accelerated the construction of a technological innovation centre in the Zhangjiang area. Located in Zhangjiang, Lui Che Woo Science Park will be key for SJTU as it actively plays a part in constructing a national science centre in the area, and from which to build a world-class R&D base by promoting technological innovation and extensive integration with economic and social development, thus further strengthening China's international presence and influence in relevant fields. Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization said, "SJTU is recognised for being one of the premier education institutions in China. It is renowned both at home and abroad, and has the longest history - stretching more than 120 years. Moreover, it has nurtured countless talent with adherence to its motto of "Gratitude and Responsibility". I am looking forward to the development of Lui Che Woo Science Park as it gradually becomes an internationally influential technological innovation centre, creating synergies with large-scale national science facilities and pursuing new R&D breakthroughs with other science parks. This includes the Shanghai Synchrotron Radiation Facility ("SSRF") nearby, which is one of the world's top five synchrotron light source projects and is engaged in the creation of new materials from atomic and molecular structures that are the fundamental of science."Yang Zhen Bin, Secretary of the CPC SJTU Committee, thanked Dr Lui for his generous support for the university, and said, "Dr Lui Che-woo selflessly promotes the advancement of mankind and encourages technological innovation through extraordinary wisdom. His assistance in the development of Lui Che Woo Science Park will boost the national technological innovation strategy and education development at SJTU. Lui Che Woo Science Park will lead SJTU as it integrates into the Zhangjiang Comprehensive National Science Centre and participates in the construction of a globally influential technological innovation centre. Through the steadfast attention of Dr Lui Che-woo and his family, we believe that Lui Che Woo Science Park will grow into an innovative platform for cross-disciplinary research; achieving major scientific breakthroughs, attracting top and innovative talent and utilising industrial technologies. "Optimise R&D conditions to attract and train professionals and consolidate China's international position in the R&D field As the primary technological innovation centre in Shanghai and a top national high-tech base, Zhangjiang Science Park possesses sizeable and comprehensive facilities, platforms, and superb institutes. Lui Che Woo Science Park is positioned as a world-class influential technological innovation centre, and is set to create a strong cluster effect with other large-scale national scientific facilities in the area. It is expected to promote the leapfrog development of multiple disciplines in China, build a cutting-edge interdisciplinary research platform, and become the centre for gathering top scientists. Lui Che Woo Science Park covers a GFA of over 100,000 square meters, half of which is for R&D use. There are eight buildings in total, housing more than 1,200 researchers from various disciplines which includes approximately 600 researchers, postdoctoral fellows, and about 600 researchers with doctoral and master degrees. They will mainly focus on the R&D of health, biomedical engineering and new materials.Seven centres and one platform support interdisciplinary scientific researchLui Che Woo Science Park houses seven research centres, including the AI Biomedicine Centre, DNA Storage and Research Centre, Integrated Scientific Innovation Research Centre, AI Cybersecurity Innovation Centre, Frontiers Science Centre for Transformative Molecules, Future Materials Creation Centre and Ultra-Fast Science Centre. Upon completion, the park will facilitate the construction of the Zhangjiang Comprehensive National Science Centre and drive China's fundamental R&D and related industrial development in interdisciplinary fields, such as physics, materials, biology, medicine and network, and so on.To facilitate collaboration among the seven research centres, the Lui Che Woo Science Park has built a public instrument platform, which currently has 65 sets of equipment worth a total of RMB137 million. It also boasts around 1,300 square meters of laboratory space, which will help further raise the standard of fundamental technologies, including element, organic molecule and molecular function analysis; providing greater and broader technical support for SJTU in terms of the detection and characterisation of such areas as organic chemistry, pharmacy, life science, medicine and material science. Furthermore, the instruments are available for teachers and students at SJTU to build a user-oriented training system. Technical training and exchanges will also be held regularly.Collaborates with SSRF to realize research results at Frontiers Science Centre for Transformative Molecules ("FSCTM")The Lui Che Woo Science Park is adjacent to SSRF, which has one of the world's top five synchrotron light source projects. The two parties have formed a strategic partnership and will cooperate in research into new molecules and materials. SSRF possesses operations that comparable to powerful "super X-ray machines" and "super microscopes", which can be used for researching in medicine, physics, science and so on.With the support from SSRF, the FSCTM at Lui Che Woo Science Park has developed the ultra-fast in-situ characterization technology. Through molecular electricity catalysis, new substances or materials can be developed for applications in medicine, clean energy and green chemicals. In 2022, results from the research team at the centre have been published by top international academic journals, such as Nature and Science.Enhances technological innovation and assists the country in implementing innovation-driven development strategiesDr Lui shares President Xi Jinping's thoughts that "science and technology are having a profound impact on the future of the country as well as on people's wellbeing like never before". He believes that there is an urgency to strengthen technological innovation to help the country play a major role in implementing development strategies and accelerating the replacement of traditional strategies with new ones.Having participated in philanthropy for nearly half a century, Dr Lui has been focusing on the support for education sector to align with the pace of national development. In particular, he is keen on supporting advanced scientific research and development in recent years, with the hope of contributing to the growth of the country. Dr Lui donated RMB120 million to the School of Life Sciences at Peking University in 2017 and RMB200 million to Tsinghua University in 2018 for the construction of two new blocks at the Biomedical Sciences Building, demonstrating his commitment to boosting life sciences development. Following these two donations, Dr Lui donated RMB250 million to SJTU to fund the construction of Lui Che Woo Science Park to support China's new and high-tech research development.Dr Lui concluded, "I migrated to Hong Kong at the age of four and have established K. Wah Group for nearly seven decades. Having witnessed the achievements of our motherland and Hong Kong in the new century, I was buoyed to uphold the belief of 'giving back to society from which one has benefited'. Technology has been developing at a rocket pace and will serve as the lifeline to people and civilization in the future. I am honoured to support SJTU's establishment of Lui Che Woo Science Park, and I hope its cutting-edge facilities and talent will contribute to scientific research and development in Shanghai and across China. I believe that the collaboration and exchange with international scientific research institutions will also boost the stature of China's scientific research in the global arena."About LUI Chi Woo PrizeFounded by Dr Lui Che-woo in 2015, the "LUI Che Woo Prize - Prize for World Civilisation" is an annual, first of its kind international cross-sector innovative award for advancing world civilisation and inspiring people to build a more harmonious world. It aims to recognise and honour individuals or organisations all over the world for outstanding contributions and encourages the continuation of that work in three objectives: sustainable development of the world, betterment of the welfare of mankind and promotion of positive life attitude and enhancement of positive energy.For more details, please go to www.luiprize.org.About K. Wah GroupK. Wah Group was founded in 1955 by Dr Lui Che-woo, who transformed the company into a multinational corporation. Core businesses include property development and investment, entertainment and leisure resorts, hospitality and construction materials. The Group has a business presence in Mainland China, Hong Kong, Macau, Southeast Asia and major cities in the US. The Group includes two Hong Kong-listed flagships: K. Wah International Holdings Limited ("KWIH"; HK stock code: 00173) and Galaxy Entertainment Group Limited ("GEG"; HK stock code: 00027 and a member of the Hang Seng Index) and over 200 subsidiaries, includes Stanford Hotels International and K. Wah Construction Materials Limited.Website: http://www.kwah.comMedia Enquiries:K. Wah GroupHelen Cheung Tel: (852) 2960 3739 Email: helencheung@kwah.com Jenny Tse Tel: (852) 2960 3101 Email: jennytse@kwah.com Andrey Leung Tel: (852) 2960 3364 Email: andreyleung@kwah.com Fax: (852) 2811 9710Lui Che Woo Prize - Prize for World CivilizationBrenda Kan Tel: (852) 2960 3791 Email: brendakan@luiprize.orgStrategic Financial Relations LimitedIris Lee Tel: (852) 2864 4829 Email: iris.lee@sprg.com.hk Shelly Cheng Tel: (852) 2864 4857 Email: shelly.cheng@sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Handover of National Centre for Pandemic and Infection Diseases in Myanmar; Advanced Facility Built with Donation from AW Foundation

YANGON, Myanmar, Nov 5, 2022 - (ACN Newswire via SEAPRWire.com) - AW Foundation, the philanthropic arm of Asia World Group of Companies, handed over to the Ministry of Health the newly completed Wai Bar Gi New Wing - National Centre for Infectious Diseases on 3rd Nov, 2022. Dedicated to the treatment of infectious diseases and pandemics such as COVID-19 which exerted heavy patient load on the public healthcare sector, it is the most advanced medical centre to date in Myanmar. The Newly-Constructed Wai Bar Gi New Wing- National Centre for Infectious DiseasesSide Views of Wai Bar Gi New Wing- National Centre for Infectious Diseases Interior Views of Wai Bar Gi New Wing- National Centre for Infectious Diseases Lieutenant General Aung Lin Dwe, the secretary of the State Administration Council, unveiled a plaque commemorating the handover of the three-story, 110-bed medical Centre, which was completed with a donation of 6 billion kyats and USD 3.1 million from the Foundation.The Wai Bar Gi New Wing was mooted in November 2020 by the AW Foundation team based on the personal experience of colleagues during the COVID-19 pandemic. The lack of quarantine hospitals, beds, and oxygen supply, and critically, the exposure of the devoted medical frontliners taking care of patients in general hospitals were gaps in the healthcare system evidenced during the critical period. The 51,055 square feet (4,745sqm) Centre is equipped with airflow control (negative-positive pressure), integrated oxygen access, isolation rooms, and water treatment and features that combine to make it one of the most technologically-advanced public healthcare facilities in the country. AW Foundation believes the new Centre will support the public healthcare system for the treatment of COVID-19 and any future pandemic. Construction of Centre A ground-breaking ceremony was held on-site on 5 January 2021. Construction was delayed due to a nationwide lockdown arising from the pandemic.The Centre is equipped with:- Donning and Doffing for medical staff- Staff corridors and lifts for use by Patients and Staff- Air-Conditioning and Mechanical Ventilation (ACMV) for full-time automatic disinfection of the air-flow system in the hospital building- Room communication systems and other electrical communication facilities (PABX, PA & Intercom) - Sound-Proof Generator for emergency use- Emergency response alarm systems that can automatically respond to fire and various natural disasters (fully equipped as required for an infectious disease treatment hospital)Sustainable Garden Hospital The Centre was conceptualized and constructed with deep consideration of the environment. Sustainable solar energy and the creation of new greenery at the Centre also create an environment to enhance the recovery process of patients and the well-being of the healthcare community.About AW Foundation (AWF) - Together, we can make change happenAW Foundation is a non-profit organization and the philanthropic arm of the Asia World Group of Companies. AWF supports projects that develop the well-being of the people of Myanmar, focusing on healthcare, education, disaster relief, and community development. It was established in 2014, building on a strong tradition of philanthropy of the Asia World Group of companies since 1992.AW Foundation aims to develop and advance the livelihoods of people throughout Myanmar and is passionate about exploring new projects that benefit all. Through our commitment to quality and continued efforts to help those in need, AWF strives to deliver exceptional value and improve the lives of Myanmar's citizens. https://aw-foundation.org/For media queries, please contact the AW Media Office at media@aw-foundation.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare and AXA Jointly Establish the FIRST AXA Medical Centre

HONG KONG, Sep 8, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group has entered into a non-legally binding memorandum of understanding (the "MOU") with AXA Hong Kong & Macau ("AXA") for a strategic partnership, pledging to work together to provide premium and comprehensive health management services to customers. EC Healthcare and AXA signed Memorandum of understanding today to kick start their long term collaboration. (From left: Emily Li, Chief Employee Benefits & Wellness Officer, AXA Hong Kong and Macau, Sally Wan, Chief Executive Officer of AXA Greater China, Eddy Tang, Founder, Chairman, Executive Director and CEO of EC Healthcare and Leslie Lu, Executive Director and Co-CEO of EC Healthcare)Under the partnership, the first AXA Medical Centre was unveiled today on the 34th floor of the World Trade Centre in Causeway Bay. Together with the AXA designated Endoscopy and Day Surgery Centre in Central, it will officially start operating in November this year.Located in the central business district of Causeway Bay, the AXA Medical Centre occupies a floor area of over 5,000 sq. ft. The center offers services include preventive medicine, body checks, vaccinations, and nutritional counselling with support from on-site medical professionals including general practitioners, Chinese medicine practitioners, dieticians and radiographers. The AXA Medical Centre provides various body check services such as chest and abdominal X-rays, ultrasound scans, gynaecological examination, electrocardiogram (ECG) with over 10 body examination rooms. Other services include allergy tests, non-invasive genetic screening tests for colorectal cancer, and all pre-insurance health screening for AXA customers.EC Healthcare is building a one-stop, multi-disciplinary, enclosed healthcare service platform, which allows AXA's customers to obtain a seamless medical referral service after check-ups and enjoy comprehensive, high-quality medical services that covers multiple medical disciplines.In addition to setting up dedicated medical centres, the Group and AXA will further their cooperation with a view to extending the market coverage of their services to other central business districts and residential areas.Mr. Leslie Lu, Executive Director and Co-CEO of EC Healthcare said, "Hong Kong's private healthcare market has huge potential. The Group regards strategic partnership with insurance firms as a key strategy of building up its presence in the growing market. The Group is very honoured to form partnership with such an internationally leading insurance group as AXA. The Group believes that the strategic partnership will boost higher customer public traffic with strong synergy in the healthcare sector and enhance the organic growth of the Group's medical and healthcare business through the provision of high-quality and high-end branding medical and healthcare services. The Group will also forge ahead with its deep strategic cooperation with the key players in the technology, telecommunications, insurance, property and pharmaceutical industries so as to keep enriching EC Healthcare's enclosed healthcare ecosystem."Ms. Sally Wan, Chief Executive Officer of AXA Greater China said, "AXA Medical Centre marks a major milestone for us in delivering exceptional health management services to our customers, providing our customers with all-round care across their life stages. The centre, offering comprehensive one-stop health management services spanning prevention, diagnosis, and treatment, not only enhanced AXA's health management ecosystem but also brought to life our ongoing commitment to become a lifelong partner to our customers. AXA and EC Healthcare share the same vision of improving our customers' holistic wellness. Through this partnership, we can bring an exclusive, innovative, and personalised healthcare experience beyond insurance to our customers leveraging our combined strength."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk Tel: (852) 2136 6952 / 2169 0467 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Provides Healthcare Services for Signature and Prestige Banking Customers of Hang Seng Bank

HONG KONG, Jul 18, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the Group will provide diversified healthcare services for Signature and Prestige Banking customers of Hang Seng Bank via the brands under the Group, including New York Medical Group, Hair Forest, DR REBORN and ATO HAIR CLUB. As the leading healthcare services provider, EC Healthcare is committed to providing professional, premium and diversified medical healthcare services covering 29 medical disciplines and to bringing health, beauty and happiness to the world. EC Healthcare will safeguard the health of banking customers in line with the client-centric core value, and provide comprehensive healthcare, aesthetic and beauty and kids well-being and healthcare services for them and their children. The promotion period started from 1 July 2022 and will end till 30 June 2023.*Please refer to the [Terms and Conditions] on the Hang Seng website for detailed information.About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, focusing on preventive and precision medicine, the leverage investment in IT, brand, service and corporate culture aims build a diversified enclosed healthcare ecosystem, bringing health, beauty, and happiness to everyone. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic Premier Medical Centre, Specialist Central and New Medical Centre, a paediatric centre PrimeCare, a gynaecology specialist Zenith Medical Centre and Paternal Diagnosis Centre, PathLab Medical Laboratories, Ophthalmology Center Vivid Eye, and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Imperial College London and Hitachi to launch a joint research centre for decarbonisation and natural climate solutions

LONDON, Jul 12, 2022 - (JCN Newswire via SEAPRWire.com) - Imperial College London (Imperial), Hitachi, Ltd. and Hitachi Europe Ltd. (Hitachi) today announced that they have signed an agreement to establish a joint research centre for decarbonisation and natural climate solutions. Together, they will collaborate in fundamental and applied research, addressing key challenges in decarbonisation and climate repair in order to achieve a Net Zero future.The new Centre, named the "Hitachi-Imperial Centre for Decarbonisation and Natural Climate Solutions" will enable a fundamental and applied research programme to be established where Imperial and Hitachi will collaborate on selected research projects, reports and white papers on the challenges and technologies in reaching net zero, as well as potential scenarios that could arise when the world reaches net zero. The Centre will also help train the next generation of scientists and engineers in the field.Initial research projects will focus on carbon management, the decarbonisation of energy and transport, carbon dioxide removal and biodiversity, with a focus on new technologies and nature-based solutions. The Centre will be a platform to bring together researchers from different faculties and disciplines, to build a truly multidisciplinary, holistic programme, taking a systems-thinking approach to embed both technical and socio-economic/policy aspects to deliver transformative and translatable solutions.Imperial is committed to helping societies become more sustainable through bold initiatives that find meaningful solutions to climate change. Imperial's Transition to Zero Pollution initiative aims to build new partnerships between research, industry and government - from fundamental science and engineering, systems thinking, human health, new business models, and policymaking - to realise its vision of a sustainable zero pollution future.Hitachi's Environmental Vision is to realise a decarbonised and resource-efficient society in harmony with Nature, and thereby contribute to a sustainable society flourishing within planetary boundaries and enhancing human well-being. To underline its commitment to a net zero society and become a Climate Change Innovator, Hitachi joined the United Nations Race to Zero Campaign in 2020, was a principal partner of COP26, and has been advocating a holistic approach to combating climate change together with stakeholders. Building on its strong presence in the mobility and energy sectors in Europe, Hitachi will leverage the global footprint and green products portfolio of the Hitachi group to deploy economically viable impactful end-to-end green solutions.Projects under this collaboration will be steered jointly by senior representatives from both Imperial and Hitachi, including Professor Mary Ryan from Imperial's Faculty of Engineering, and Dr Kazuyuki Sugimura, CTO of Hitachi Europe Ltd.Professor Ryan, who also leads the Transition to Zero Pollution initiative, said: "There is greater urgency than ever before to tackle global pollution, of which CO2 is one of the biggest sources. This joint research centre will bring together world-leading scientists and innovators in decarbonisation and climate repair to develop new technology and solutions to the climate emergency. Imperial and Hitachi will work closely together to make significant advances in developing cleaner energy and this new centre will accelerate our work towards a zero pollution future." Dr David Green, collaboration centre lead for Hitachi and Head of the Sustainability Laboratory in the European R&D Centre of Hitachi Europe Ltd. said: "Limiting greenhouse gas emissions and reaching Net Zero is crucial. Yet even in a net zero world we will still face serious societal and environmental challenges caused by high residual levels of carbon dioxide in the atmosphere. We are excited to open our new centre with Imperial which builds on previous collaborations and harnesses their expertise in scientific research, business and policy."About Imperial College LondonImperial College London is one of the world's leading universities. The College's 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business.Imperial is University of the Year 2022 in the Times and Sunday Times Good University Guide. It is the world's fifth most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. Imperial has a greater proportion of world-leading research than any other UK university, according to the Research Excellence Framework (REF). Imperial ranks first in the UK for research outputs, first in the UK for research environment, and first for research impact among Russell Group universities.About Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company's consolidated revenues for fiscal year 2021 (ended March 31, 2022) totalled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.About Hitachi Europe Ltd.Hitachi Europe Ltd., a subsidiary of Hitachi, Ltd., is headquartered in Sefton Park, UK. The company is focused on its Social Innovation Business - delivering innovations that answer society's challenges. Hitachi Europe and its subsidiary companies offers a broad range of information & telecommunication systems; rail systems, power and industrial systems; industrial components & equipment; automotive systems, digital media & consumer products and others with operations and research & development Laboratories across EMEA. For more information, visit https://www.hitachi.eu/en.For more information, use the enquiry form below to contact the Research & Development Group, Hitachi, Ltd. Please make sure to include the title of the article. www8.hitachi.co.jp/inquiry/hqrd/news/en/form.jsp Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Received “Institutional Investor” 2022 Multiple Awards in All-Asia Executive Team Rankings

HONG KONG, Jun 27, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the excellent result in the "All-Asia Executive Team Rankings 2022" under the category of Healthcare & Pharmaceutical organized by Institutional Investor, an international magazine. The Group is delighted recognize as The Most Honoured Company (Healthcare & Pharmaceutical) in the division - Asia (excluding mainland China), which represents recognition of the Group's impressive performance by the investors and the market. Recognized as an authoritative ranking by industries, "All-Asia Executive Team Rankings" celebrates the outstanding companies and management teams in Asia. Buy-side and sell-side analysts rated the listed companies within the scope of their research according to several criteria used in evaluating performance in corporate governance.Category / AwardCore Asia Results / Best IR TeamAsia ex-Mainland China:The Most Honoured CompanyBest CEO - Mr. Eddy TangBest CFO - Mr. Levin LeeBest Investor Relations Program Best ESGBest Investor Relations Professional - Mr. Christopher Wong / Ms. Hermione HeAsia Small and Midcap:Best CEO - Mr. Eddy TangBest CFO - Mr. Levin LeeBest Investor Relations Program Best ESGBest Investor Relations Professional - Mr. Christopher WongMr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group is honoured and grateful to receive these awards. We will continue to spare tremendous effort with the aim of further consolidating the leading position in the healthcare market and maximizing our shareholder value. The Group wishes to excel together with our much-valued stakeholders and stay proactive in continuously refining our strategies for the overall welfare of our company and the greater community."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, a advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Malaysian Genomics Resource Centre Berhad Gets Affected Issuer Status Uplifted

PETALING JAYA, Malaysia, Jun 13, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that it is uplifted from being classified as an affected listed corporation effective 13 June 2022.Azri Azerai, Executive Director of Malaysian GenomicsSasha Nordin, CEO and Dato' Alvin Nesakumar, Executive Director of Malaysian Genomics [L-R]This followed the decision by Bursa Securities Malaysia Berhad to grant the Group a waiver in submitting a regularisation plan after being classified as an affected listed corporation pursuant to Rule 8.03A of the Listing Requirements. Bursa Securities had made the classification according to Rule 8.03A on 24 December 2019 and Malaysian Genomics had submitted an application seeking approval to exempt the Group from submitting a proposed regularisation plan on 24 March 2022. The waiver was granted on 10 June 2022.Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "I am extremely thankful to the team for working diligently to get Malaysian Genomics out of the affected issuer classification status and welcome this news from the regulator. Our diversification into biopharmaceutical services, in particular the distribution of immunotherapy and cell therapies, has supported the financial performance of the Group. I believe that we can grow together, as a team."In a recent announcement on its 3Q 2022 performance, Malaysian Genomics reported a profit before tax (PBT) of RM1.96 million compared with PBT of RM0.2 million in 3Q 2021. Earnings per share (EPS) stood at 1.60 sen for 3Q 2022 compared with EPS of 0.19 sen in the corresponding quarter of the previous financial year.Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, "We will continue to seek opportunities through collaborations and partnerships targeting new consumer and market segments, including those beyond Malaysia, as we strive to widen our reach and capitalise on heightened awareness on health issues across the region and farther afield. We look forward to introducing new products and markets in the near future."Dato' Alvin Nesakumar, Executive Director of MGRC, said, "As we have shared before, we are also moving towards offering our products and services through adopting a business-to-consumer strategy to complement our business-to-business approach because trends are changing and technology enables us to reach out directly to consumers. This new approach will give us better insight into what the market needs."Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK] Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Malaysian Genomics Resource Centre Berhad Posts 212% Increase in Revenue for 3Q FY2022

PETALING JAYA, Malaysia, May 23, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group registered a 211.66% increase in revenue to RM5.08 million for the third quarter ended 31 March 2022 (3Q 2022) compared with revenue of RM1.63 million for the same quarter of the previous financial year.Azri Azerai, Executive Director of Malaysian Genomics Resource Centre BerhadFor the quarter under review, the Group posted profit before tax (PBT) of RM1.96 million compared with PBT of RM0.2 million in 3Q 2021. Earnings per share (EPS) stood at 1.60 sen for 3Q 2022 compared with EPS of 0.19 sen in the corresponding quarter of the previous financial year.For the nine months ended 31 March 2022 (9M FY2022), Malaysian Genomics registered a nearly 12-fold increase in revenue to RM22.03 million compared with RM1.85 million in 9M FY2021. The Group registered RM3.21 million in PBT for 9M FY2022 compared with a loss before tax of RM2.2 million in the corresponding period of the preceding financial year.Encik Noor Azri bin Dato' Sri Noor Azerai (Azri Azerai), Executive Director of Malaysian Genomics, said, "The improvement in revenue for the quarter under review was due to the Group's diversification into biopharmaceutical services, primarily the distribution of immunotherapy and cell therapies, together with higher demand for genetic screening services following the reopening of the economy. COVID-19 vaccine administration and distribution contributed to our revenue growth as well.""Our PBT was supported by higher margin from the Group's successful and ongoing penetration into the distribution of immunotherapy and cell therapies. We continue to seek partnerships and opportunities in which we can have a wider market reach for our services, while our laboratory's Current Good Manufacturing Practice approval will add value to our capabilities, including the production of CAR T-cells for solid cancers as well as the contract manufacturing of other types of cells for third-parties that will generate new revenue streams."Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK] Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Malaysian Genomics Resource Centre Berhad Supports Yayasan Seri Negara’s Ramadhan Initiative

PETALING JAYA, Malaysia, Apr 28, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to support Yayasan Seri Negara's (YSN) Ihya Ramadhan 2022 programme through a monetary donation to help those in need.Dato' Seri Mazlan Lazim, Patron of Yayasan Seri Negara and Encik Azri Azerai, Executive Director of Malaysian Genomics Resource Centre [L-R]The Ihya Ramadhan 2022 programme will be held in several locations throughout the country and involves the breaking of fast and the giving of monetary aid to orphans and the underprivileged.Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "We are happy and honoured to be able to assist YSN in their Ihya Ramadhan 2022 programme. Every little bit helps, and we want to do our part in easing the burden of those in need such as orphans and the underprivileged."Malaysian Genomics' cash aid will be distributed to orphans and the underprivileged at the Shah Alam district police headquarters during the Ihya Ramadhan 2022 programme held at the location on 27 April 2022 at 6pm.Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK] Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Malaysian Genomics Resource Centre Berhad Awarded Covid-19 Surveillance Contract

PETALING JAYA, Malaysia, Apr 4, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research ("IMR"), the biomedical research arm of the Ministry of Health ("MOH"). Malaysian Genomics is one of the private laboratories that IMR has engaged to outsource genome surveillance of SARS-CoV2.Dato' Alvin Nesakumar, Executive Director of Malaysian Genomics Resource Centre BerhadDato' Alvin Nesakumar, Executive Director of Malaysian Genomics, said, "We are pleased to support IMR and MOH in this important effort to monitor the evolution of the COVID-19 virus, its variants and sub-variants. With our expertise and knowledge in genomics and bioinformatics, we can help IMR track and trace the virus for any variants of concern that the Government needs to be informed of as well as prepare for."Malaysian Genomics, whose cell laboratory is the only privately-owned BioSafety Level 2 ("BSL-2") facility in Malaysia with the Current Good Manufacturing Practice ("cGMP") certification, is moving towards becoming a premier healthcare provider through the production of CAR T-cells for cancer immunotherapy for solid cancers, as well as other cell engineering services. BSL-2 and cGMP certifications indicate that a laboratory facility has stringent measures for biocontainment standards and ultra-pure laboratory environments to safely work on human cells.The Group is also ISO 9001:2015, ISO 15189:2014 and ISO 17025:2017 certified under the Integrated Management System.Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Opens New Multi-Service Flagship Medical Centre at Central and Advanced Imaging Centre at Taikoo

HONG KONG, Apr 4, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's new multi-service flagship medical centre ("New Flagship Centre") located in Central and its new advanced imaging centre located in Tai Koo have commenced operations on 31 March 2022 and 1 April 2022 respectively, thus further expanding the Group's market share in the medical market.The New Flagship Centre is located at Fung House in Central, Hong Kong Island, with seven new floors with an aggregate gross floor area of approximately 22,000 square feet. The upper five floors of the New Flagship Centre offer services including but not limited to general medical, orthopedics, ophthalmology, chiropractic, physiotherapy and pain management and service centres have commenced operations. The other two floors will be an advanced imaging centre serving as a one-stop medical imaging service hub, which is expected to commence operation in the fourth quarter of 2022.In addition, the gross floor area of another new advanced imaging centre is located on 6/F of Cityplaza in Tai Koo, Hong Kong Island is approximately 3,400 square feet. After this expansion, the Group operates six advanced imaging centres across the New Territories, Kowloon and Hong Kong Island, thereby further improving its service network. Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "EC Healthcare has been developing preventive and precision medicine as its core businesses. To fulfill the strong demand for medical services, the Group has established the related service centres through organic growth in an effort to further exploit business synergy among its diversified medical and healthcare businesses. The Group will remain committed to building up an enclosed healthcare ecosystem focused on satisfaction of customers in order to provide quality one-stop services to the customers and consolidate the Group's industry leadership as a one-stop comprehensive healthcare and medical service provider."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the MSCI Small Cap Index and the Hang Seng Composite Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Launch Tele-Medicine and Drug Delivery Service, Reduce Infection Risk and Protect Citizen’s Health

HONG KONG, Mar 9, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce, to reduce the infection risk from going out for medical consultation, the Group launch Tele-Medicine service under EC Healthcare Medical Centre, AI MEDICAL, PRIMEcare, chiropractor and traditional medicine services under NYMG. The Group's professional medical team will fully be devoted to providing services to the public. The Group formed a dedicated team that can provide 500 session telemedicine services per day at the first phase and will continue to scale up to match the demand from our clients.Please book via EC Healthcare online platform: https://ectelemedicine.echealthcare.com/If you have any enquiry, please contact Customer Service Hotline: 2152 8503The Tele-Medicine mainly provides common diseases consultation and chronic disease follow-up consultation. The teleconsultation can cover flu, diarrhea, rash, sinusitis, red eye, indigestion, diabetes, hypertension and hyperlipidemia. After the teleconsultation, the Group will also arrange a drug delivery service within four hours*. This service helps citizens to manage health conditions at home.Apart from teleconsultation, the Group's service centers located in each district include general outpatient clinics, specialist clinics, health check centers, vaccine centers and laboratory centers still commence usual operation and provide vaccine, pre-vaccine body check, PCR test and antibody test. The Group is devoted to being the public's health guardian, serving the community, and contributing to the anti-epidemic work.*Drug delivery service arrive time is subject to prevailing conditionsAbout EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

UMP Healthcare Offers Free Telemedicine Service to COVID-19 Patients

HONG KONG, Feb 23, 2022 - (ACN Newswire via SEAPRWire.com) - UMP Healthcare Holdings Limited ("UMP" or the "Group"; SEHK: 722) has announced that its affiliate, UMP Charity Foundation Limited (the "Charity Foundation"), will donate first batch of donation of HK$500,000 to support patients diagnosed with COVID-19 through the provision of free medical video consultation, or 'telemedicine' services and the expansion of the Sinovac vaccination service at the Group's medical centres. It is anticipated that at least 10,000 people in need will benefit from these services in the next month. An additional donation may be committed when needed.Telemedicine service allows patients to get the doctor's immediate advice without leaving home.As the number of new COVID-19 cases rapidly increases, patients with confirmed infections are stuck at home waiting for hospital admission or in isolation, and many elderly people, adults, and children urgently need medical consultations. UMP will provide free telemedicine services for relevant patients in response to current needs and the Hospital Authority's call to support anti-epidemic efforts. Patients who have been confirmed infections, preliminary infections or have self-tested positive using rapid antigen tests can register online for the service. A video consultation with a doctor will be arranged during designated service hours and they will be provided with any required medication if necessary. The consultation could help to alleviate patients' concern and enable them to receive treatment without leaving their home. Donations from the Charity Foundation will fully subsidise the costs of the consultation services, medicine and support for all related matters.In addition, given the rapid increase of vaccination demand, 11 of the Group's medical centres are gearing up to support the Sinovac vaccination service. UMP will also set up an additional vaccination point at the UMP Wellness & Metabolic Centre in Central to provide extra services for seniors and children, who are considered priority groups for protection. There will be specialist doctors and registered nurses in attendance at the centre to evaluate those who wish to be vaccinated and confirm their recommendations. They will also answer questions and follow up with those who have received the vaccination, reducing anxiety and worries of those in need.Dr. Sun Yiu Kwong, Chairman and CEO of UMP, and Director of UMP Charity Foundation, said, "UMP hopes to fulfil its responsibilities as a corporate and professional medical institution to help the public amid the severe epidemic in Hong Kong. Our medical team is also ready to do its best to reduce the pressure on the public medical system, provide support to those in need and have a positive impact on society. Meanwhile, we express our condolences to those affected by the epidemic and hope that our actions can provide immediate warmth."Telemedicine service hours are Monday to Friday, 9am to 6pm, with limited service available in the evenings and Saturdays. To register, please visit https://bit.ly/3H2IzY8.Sinovac vaccination services are provided at the following locations. Service hours vary by individual centre. For enquiries, please call the respective medical centre.UMP Medical Centre (Central) Address: 14/F, Wing On House, 71 Des Voeux Road CentralPhone: (852) 2840 1636UMP Wellness & Metabolic Centre (for seniors and children)Address: Room 1603, 16/F, Wing On House, 71 Des Voeux Road CentralPhone: (852) 2507 2656UMP Medical Centre (Causeway Bay) Address: Room 1901C, 19/F, East Point Centre, 555 Hennessy Road, Causeway BayPhone: (852) 2811 8218UMP Medical Centre (Wanchai)Address: Room 1109, Office Tower, Convention Plaza, 1 Harbour Road, Wan ChaiPhone: (852) 2824 0018UMP Medical Centre (Jordan)Address: Room 03-04, 15/F, 238 Nathan Road, JordanPhone: (852) 3549 6833UMP Medical Centre (Tsim Sha Tsui)Address: Room 7, 10/F, Wing On Plaza, 62 Mody Road, Tsim Sha Tsui EastPhone: (852) 2369 9536UMP Medical Centre (Olympic)Address: Unit 2, 1/F, Skyway House,3 Sham Mong Road, TaikoktsuiPhone: (852) 2740 4319UMP Medical Centre (Kwun Tong)Address: G/F, 183 Hip Wo Street, Kwun TongPhone: (852) 2855 8098UMP Medical Centre (Kowloon Bay)Address: Shop F, G/F, Tak Bo Garden, 3 Ngau Tau Kok Road, Kowloon BayPhone: (852) 2751 9339UMP Medical Centre (Tsuen Wan)Address: Shop 1070, Level 1, D-PARK, 398 Castle Peak Road, Tsuen WanPhone: (852) 2940 1338UMP Medical Centre (Shatin)Address: Shop 9, G/F, Ming Yiu Lau, Jat Min Chuen, ShatinPhone: (852) 2634 1812UMP Medical Centre (Park Island)Address: G/F, No.21 Ma Wan Main Street Village East, Ma WanPhone: (852) 2986 3880About UMP Healthcare www.ump.com.hkFounded in 1990, UMP Healthcare Holdings Limited is one of the largest and longest listed medical groups in Hong Kong, and is listed on the main board of the Hong Kong Stock Exchange (stock code: 722.HK). The company has been providing trusted and affordable medical services for 32 years, giving people peace of mind to focus on living their lives to the fullest without worrying about their health. The company is committed to helping people improve their health and winning the fight against the epidemic together.In addition to healthcare services that cater to diverse individual needs, UMP works closely with corporates and insurance companies to customize and administer corporate healthcare benefits plans for their members. The current UMP network boasts more than 1100 self-owned and affiliated medical service points across Hong Kong and Macau, providing services including family medicine, specialist consultation, dental care, diagnostic imaging and laboratory, preventive medicine and health assessment, day surgery and endoscopy. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

EC Healthcare Opens New Healthcare Medical Centre, Further Consolidate the Leading Position and Expand Market Share

HONG KONG, Feb 14, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that, to fulfill the strong demand for medical and healthcare services, the Group is opening a new healthcare medical centre and advanced imaging centre at Cityplaza in Tai Koo,Hong Kong Island, with two newly leased floors with an aggregate gross floor area of approximately 12,300 square feets.The newly leased floors on 14/F of Cityplaza is the EC Healthcare Medical Centre which offers services including but not limited to general medical, specialist, dental and pain management services with a gross floor area of approximately 8,900 square feets and the centre is in full operation from 11 February 2022. The other newly leased floor on 6/F of Cityplaza is an advanced imaging centre serving as a one-stop medical imaging service hub with gross floor area of approximately 3,400 square feets, which is expected to commence operation in March 2022. Together with this new imaging centre, the Group shall have four advanced imaging centres across the New Territories, Kowloon and Hong Kong Island by March 2022.The Board believes the aforementioned expansion will become a growth driver for the Group's businesses, further consolidate the Group's position in the industry as a one-stop comprehensive healthcare and medical service provider, and effectively expand its healthcare and medical market share. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

HMI Group Strengthens Specialist Offering, Acquires Majority Stake in Eagle Eye Centre

- The acquisition bolsters HMI Group's offering of complete one-stop healthcare services and capabilities to patients in Singapore and the region- The partnership strengthens HMI Group and EEC's market position in Southeast Asia, and positions HMI Group for continued growth, synergies, and expansionSingapore, Jan 24, 2022 - (ACN Newswire via SEAPRWire.com) - Health Management International Pte Ltd (HMI Group), a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia, has acquired a majority stake in Eagle Eye Centre Pte Ltd (EEC), the largest private ophthalmology chain in Singapore."With our investment, we will partner with EEC and work closely with the EEC doctors to grow the business locally and in the region," said Ms Chin Wei Jia, Group Chief Executive Officer of HMI Group. "This is a significant step in expanding HMI Group's portfolio into the specialist medical services as we strive to provide one-stop healthcare services both within and outside of hospitals."Founded in 2006, EEC started out as a one-stop specialist eye care facility, and was amongst the first to offer comprehensive ophthalmic care with services in all eye subspecialties under one roof. Today, EEC operates a chain of seven ophthalmology centres in Singapore together with 17 resident eye specialists. EEC offers a full suite of ophthalmic subspecialties including Cornea and Anterior Segment; Ocular Immunology and Uveitis; Cataract; Refractive Surgery; Glaucoma; Medical and surgical Retina; Neuro-Ophthalmology; Paediatrics and Strabismus; and Oculoplastic.Delivering convenience and valueThe EEC acquisition complements the Group's Singapore strategy, which focuses on providing quality and patient-centred healthcare services outside of hospitals that are convenient and delivers value. Furthermore, it will accelerate HMI Group's journey to capture the growing global trend of day surgery procedures, especially in developed markets, as medical skills and technology continue to advance. In Singapore, about 50% of surgical procedures can be performed in day surgery setting. "With HMI Group's expertise and reach in the region, we will continue to enhance access to high quality healthcare services for the people we serve. Through our investments in non-hospital settings, we are better prepared to deliver care in the future of health. HMI Group has a unique opportunity to use the momentum for change created by the COVID-19 crisis to accelerate the transformation of outpatient care," Ms Chin said. "We will also have the collective experience and extensive track record of Dr Julian Theng, Dr Lim Wee Kiak, and EEC's team of highly skilled sub-specialised ophthalmologists, to provide comprehensive optometric and ophthalmic care. We look forward to supporting EEC's growth ambitions and are excited to welcome the team into the HMI family."Expanding into specialist eye centres also enhances HMI Group's portfolio of primary care clinics and ambulatory care centres in Singapore. EEC recently built operating theatres and day procedure suites in King Albert Park and Royal Square Novena to perform common day surgery procedures such as Cataract and LASIK procedures outside of a hospital setting. The EEC acquisition is HMI Group's second in 2021. In September, HMI Group acquired a majority stake in OneCare Medical, a chain of 25 primary care clinics in Singapore. Through organic growth and the 2 new acquisitions, HMI Group's EBITDA has grown about 70% since HMI Group de-listed in December 2019 in a management buy-out together with EQT, a global investment firm, to now become one of the largest privately held healthcare providers in Southeast Asia."Joining HMI Group presents a strategic opportunity for us to extend our ophthalmic services not just locally but regionally. We are thrilled to have found a purpose-driven, like-minded partner in HMI Group. With a common heart in a patient-centric approach to healthcare, while trusting us to continue leading in the ophthalmic medical management of EEC, our collective aim is to make a positive impact in our communities as we grow together," said Dr Julian Theng, Group Chairman and Medical Director of EEC. "We are optimistic about the further development of our business while tapping on synergies across the Group to better serve our patients."About Health Management International Pte Ltd Health Management International Pte Ltd ("HMI" or the "Group") is a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Group owns and operates two tertiary hospitals in Malaysia. In Singapore, the Group owns and operates a healthcare training centre, a primary care clinic chain with 25 locations, and Singapore's first private one-stop ambulatory care centre. The Group also has a network of representative offices in Indonesia, Malaysia and Singapore.Established in 1994, Mahkota Medical Centre ("Mahkota") is HMI Group's flagship hospital located in the heart of Malacca and is the first JCI-accredited hospital in Malacca. The 340-bed hospital is the largest private tertiary hospital in South Malaysia, and is the first and only hospital in Malacca to offer nuclear medicine and kidney transplant services. Mahkota sees close to 100,000 international patients per year and was named the "Malaysia Medical Tourism Hospital of the Year" by Frost & Sullivan in 2015 and 2016.The Group's second hospital, Regency Specialist Hospital ("Regency") was launched in 2009 and is one of the fastest growing private tertiary hospitals in Malaysia located in the state of Johor. The 218-bed Regency is the only private hospital in Malaysia with a 24-hour Emergency & Trauma Centre, providing round the clock specialist attention and medical care to both local and international patients. Regency is in the midst of building a major hospital extension block to increase capacity up to 500 beds. The Group holds a majority stake in StarMed Specialist Centre ("StarMed"), a one-stop day-surgery and multidisciplinary medical centre that offers quality clinical services at competitive private sector prices. The Group also holds a majority stake in OneCare Medical, a fast-growing primary care clinic chain with 25 clinics across Singapore. HMI Group's healthcare training centre, the HMI Institute of Health Sciences, is the Group's Social Enterprise arm and a SkillsFuture Singapore accredited Continuing Education and Training Centre for the healthcare support sector. For more information, please refer to www.hmi.com.sg.About Eagle Eye Centre Pte LtdEstablished in 2006, Eagle Eye Centre Pte Ltd ("EEC") is the largest private ophthalmology chain in Singapore. EEC operates a chain of 7 ophthalmology centres in Singapore together with 17 resident eye specialists. EEC offers a full suite of ophthalmic subspecialties including Cornea & Anterior Segment, Ocular Immunology & Uveitis, Cataract, Refractive Surgery, Glaucoma, Retina, Neuro-Ophthalmology, Paediatrics & Strabismus and Oculoplastics.EEC is committed to deliver quality eye care treatment at affordable prices that can best serve the mass community and constantly invests in technology to keep up with its pace. EEC was recognised as the Ophthalmology Service Provider of the Year by Global Health Awards for the past 5 consecutive years. For more information, please refer to www.eagleeyecentre.com.sg.Contact: Chi-an Chang, Director, Financial PRChi-an@FinancialPR.com.sg Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

HMI Group Expands Singapore Presence, Doubles Down on Value-based Care Offering

- HMI Group is increasing its investment in OneCare, a chain of private primary care clinics in Singapore- Since HMI Group's initial minority investment in 2018, the number of clinics OneCare operates has more than doubled from 12 to 25 to better serve the Singapore population- The investment is in line with Ministry of Health's strategy to sustain quality and value-based healthcare as demand risesSingapore, Dec 10, 2021 - (ACN Newswire via SEAPRWire.com) - Health Management International Pte Ltd (HMI Group), a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia, is expanding its Singapore footprint with a majority stake purchase in OneCare Medical Group (OneCare), a chain of private primary care clinics in Singapore. The move is part of HMI Group's strategy to boost value-based care offering across the country.tion "With the investment in OneCare, we are expanding our Singapore presence and doubling down on our value-based care offering in line with the government's '3 Beyonds' push to keep healthcare in Singapore affordable and accessible," said Ms Chin Wei Jia, Group Chief Executive Officer of HMI Group.Alongside the increased stake in OneCare, HMI Group's Singapore expansion strategy includes opening as well as acquiring more private primary care clinics. At the same time, HMI Group is also broadening its offerings at its subsidiary StarMed Specialist Centre (StarMed), a one-stop ambulatory care centre that provides quality, cost-effective, convenient and comfortable experiences for patients and their families.Since HMI Group opened StarMed in 2018, the centre has doubled in size from four floors spanning some 16,000 square feet, to eight floors spanning 29,400 square feet. StarMed is equipped with day surgery theatres, endoscopy suites, radiology centre, specialist clinics and health screening centre. Plans are underway to open an orthopaedic centre, a digestive and bariatric centre and an eye centre. In addition, StarMed is also building a new patient ward floor, which includes an ICU-capable negative pressure room."Our goal is to build a value-based healthcare ecosystem that offers primary to specialist and ambulatory care in Singapore," Ms Chin said.With OneCare, HMI Group is bringing affordable and quality primary healthcare to the heartlands to better serve the population's healthcare needs, including preventativemedicine to help avoid unnecessary hospitalisations. With StarMed, HMI Group is providing a quality alternative for people to access specialist healthcare and integrated services, without the long wait times or expense of traditional hospitals. This alternative access to specialist healthcare also means people may not need to defer elective surgeries due to limited hospital capacity, which occurs periodically when hospitals need to focus on Covid-patient care."Through StarMed, we want to help free up hospital beds for more urgent life-saving treatments. Especially since StarMed can handle 60% to 70% of healthcare procedures safely outside of hospitals, and also offers ambulatory care post-surgery," Ms Chin said.Making Private Healthcare Affordable and AccessibleIn 2017, the Ministry of Health (MOH) announced the "3 Beyonds" strategy, which aims to ensure healthcare goes:1. Beyond hospitals to communities so people can receive appropriate care in the community or at home, and avoid frequent hospital admissions2. Beyond quality to value so people receive increased quality of care while ensuring value for money3. Beyond healthcare to health to encourage people to take proactive measures to stay healthyIn December 2018, HMI Group made its initial investment in OneCare with the goal of accelerating the private primary care clinics' growth to provide healthcare beyond hospitals and in heartland communities. Over the past three years, HMI Group has achieved that with OneCare's management team, which includes co-founders Dr Jimmy Chew, CEO of OneCare, and Dr Kenneth Koh, Medical Director of OneCare."Since 2018, the number of clinics OneCare operates has more than doubled from 12 to 25. Pre-covid, our clinics saw close to 450,000 visits annually, with around 90% of patients from the heartlands," Dr Chew said. "We plan to build on our achievements so far, and HMI Group's increased stake will allow us to offer personalised interactions and better healthcare experiences for more patients as we grow more clinics across Singapore."Holistic Healthcare for AllEstablished in 2013, OneCare's mission is to provide affordable private primary healthcare in Singapore through a hybrid of brick-and-mortar facilities and virtual care. OneCare clinics are Medisave and CHAS-accredited and most of the clinics are part of the various Primary Care Networks, which is the MOH's plan to have better coordinated and holistic primary healthcare in the community."HMI Group and OneCare share the same vision of delivering value-based care that's affordable and accessible," Ms Chin said. "We appreciate that OneCare clinics are well located within Singapore heartlands. These relationships built over time earns the residents' trust as important health partners providing holistic and accessible acute and chronic care serving the community's needs."Founded in 2018 in partnership with a group of specialist doctors, StarMed offers specialist care such as cardiology, gastroenterology, general surgery, orthopaedics, ENT, paediatrics, radiology and urology. The specialist centre offers competitive pricing and same-day appointments where patients could be referred from OneCare primary care clinics to receive specialist care such as scans, surgery and recovery all in one place. StarMed is on the panel for most Integrated Shield Plan and selected corporate insurance providers in Singapore. For example, StarMed is a specialist healthcare and day surgery partner on Prudential Singapore's hospital partnership programme - PRUPanel Connect."HMI Group's mission has always been to provide quality and accessible healthcare. With our Singapore expansion plans, we are looking forward to serving more people closer to their homes in the heartlands," Ms. Chin said.About Health Management International Pte LtdHealth Management International Pte Ltd ("HMI" or the "Group") is a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Group owns and operates two tertiary hospitals in Malaysia. In Singapore, the Group owns and operates a healthcare training centre, a primary care clinic chain with 25 locations, and Singapore's first private one-stop ambulatory care centre. The Group also has a network of representative offices in Indonesia, Malaysia and Singapore.Established in 1994, Mahkota Medical Centre ("Mahkota") is HMI's flagship hospital located in the heart of Malacca, a UNESCO World Heritage Site and a popular destination for medical care and leisure. The 340-bed hospital is the largest private tertiary hospital in South Malaysia, offering a comprehensive suite of healthcare services and the first and only hospital in Malacca to offer nuclear medicine and kidney transplant services. It is also a leader in Malaysia medical tourism, serving close to 100,000 international patients per year and named the "Malaysia Medical Tourism Hospital of the Year" by Frost & Sullivan in 2015 and 2016.The Group's second hospital, Regency Specialist Hospital ("Regency") was launched in 2009 and is one of the fastest growing private tertiary hospitals in Malaysia. Strategically located within the fast developing and vibrant Iskandar Malaysia, the special economic zone in the state of Johor, the 218- bed Regency is easily accessible via land, sea or air from Singapore, Indonesia and the region. Regency is in the midst of building a major hospital extension block to increase capacity up to 500 beds. It is the only private hospital in Malaysia with a 24-hour Emergency & Trauma Centre, providing round the clock specialist attention and medical care to both local and international patients.The Group holds a majority stake in StarMed Specialist Centre ("StarMed"), a one-stop day-surgery and multidisciplinary medical centre that offers quality clinical services at competitive private sector prices. The Group also holds a majority stake in OneCare Medical, fast-growing primary care clinic chain with 25 clinics across Singapore.HMI's healthcare training centre, the HMI Institute of Health Sciences, is a Skills Future Singapore accredited Continuing Education and Training Centre for the healthcare support sector. It has trained more than 4,500 healthcare professionals and 160,000 individuals in emergency life-saving skills to date.For more information, please refer to www.hmi.com.sg.About OneCare MedicalEstablished in 2013, OneCare Medical ("OneCare") is a fast-growing primary care clinic chain with 25 clinics across Singapore. OneCare offers a full range of primary care services, health screening and medical examinations for its patients. OneCare remains committed in delivering Affordable, Accessible and Quality healthcare for all patients.OneCare was named the 7th fastest growing company on the Straits Times' list of Singapore's Fastest Growing Companies in 2019. The Straits Times and Statista recognised OneCare as the 2nd fastest growing company in the healthcare sector in Singapore, and was the 158th fastest growing company in Asia-Pacific in 2020. It was also awarded the Most Trusted Preventative Healthcare Services provider 2021 by APAC Insider, recognising OneCare's ongoing commitment to bring affordable, accessible and quality primary care.For more information, please refer to www.onecaremedical.com.sg.About StarMed Specialist CentreEstablished in 2018, StarMed Specialist Centre ("StarMed") is Singapore's first private one-stop private ambulatory care centre. StarMed comprises of GP and health screening services, specialist clinics, operating theatres, endoscopy suites and radiology facilities. With more than 40 experienced doctors, StarMed's specialties include cardiology, gastroenterology, general surgery, orthopaedics, ENT, paediatrics, radiology and urology. The centre is conveniently situated above Farrer Park MRT station and co-located with the 300-room Holiday Inn Singapore Little India.For more information, please refer to www.starmedspecialist.com/Contact:Chi-an Chang, Director, Financial PR Chi-an@FinancialPR.com.sg Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More